Diligence memo · auto-generated · as of July 2, 2026
Lorus Therapeutics Inc
Lorus Therapeutics Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Lorus Therapeutics Inc operates in Biotechnology, based in TORONTO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lorus Therapeutics Inc has raised $28M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $28M on 2014-04-10.
Most recent recorded round closed around 2014-04-10.
Valuation (modeled)modeled
Provath models Lorus Therapeutics Inc at approximately $1.1B (range $57M–$4.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.57× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 12.2 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 74% of Biotechnology peers (4293 compared).
Modeled value ranks above 90% of those peers.
Closest niche peers: BioAtla,LLC, Scholar Rock LLC, Oligasis, LLC, Alector LLC, Gelesis Inc.
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.